Artios - Experts in DDR

We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells

Find out how
Cancers change their DDR pathways to allow mutations in their DNA so that they can evolve and adapt. This enables cancers to become resistant to current therapies.


Artios aims to be the leading independent DDR company with a strong array of new cancer therapies in development. Our cutting-edge DDR programmes have potential applications across a broad range of cancers

Find out how
Targeting the DDR has been clinically validated through the recent success of PARP inhibitors and the launch of Lynparza™ (olaparib; AstraZeneca).

Developed by an expert team

Working together with industry-leading partners and investors to push the boundaries in the fight against cancer

Find out who

Our Partners

Cancer Research Technology

We have in-licensed lead programmes from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and we are working in collaboration with them and other world leaders in DDR to discover and develop exciting new programmes